Regulatory policy and the location of bio-pharmaceutical FDI in Europe

Pamina Koenig and Megan MacGarvie

PSE Working Papers from PSE (Ecole normale supérieure)

Abstract: This paper examines the relationship bewteen cross-country differences in drug price regulation and the location of biopharmaceutical Foreign Direct Investment (FDI) in Europe. We use a theoretically-grounded location-choice model and data on 294 investments initiated in 27 European countries between 2002 and 2006 to test the hypothesis that biopharmaceutical companies are less likely to locate new investments in countries with more stringent price regulation.

New Economics Papers: this item is included in nep-eec and nep-reg
Date: 2009
View list of references

Downloads: (external link)
http://www.pse.ens.fr/document/wp200911.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:pse:psecon:2009-11

Access Statistics for this paper

More papers in PSE Working Papers from PSE (Ecole normale supérieure)
Contact information at EDIRC.
Series data maintained by ().